FIG 4.

EBV confers gastric cancer cells resistance to apoptosis, and BART5-3p is involved. (A, B) Cells were treated (or not treated) with 10 μM etoposide for 24 h. AGS-Akata cells were transfected (or not) with BART5-3p inhibitor for 12 h before being treated with etoposide. The protein levels of p53 were detected by Western blotting (A); the relative p53 protein level was normalized to GAPDH, and the fold changes (after/before etoposide treatment) are shown. *, P < 0.05; ***, P < 0.001 (B). (C) AGS-AKATA cells were treated with 10 μM etoposide for the indicated times. The RNA levels of CDKN1A and BART5-3p were detected by qPCR. Actin was used for normalizing the expression of CDKN1A. RPU6B (U6) was used for normalizing the expression of BART5-3p. (D) AGS-AKATA cells were transfected with NC or BART5-3p mimics for 36 h. The protein levels of p53 and p21 were detected by Western blotting.